For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- 60% of Pharmacies Claim Premiums for Generics Dispensing System: NPhA Survey
December 20, 2010
- Ain Pharmaciez to Accelerate Development of Medical Malls
December 20, 2010
- Kyowa Kirin Announces Positive Japanese PII Results on KW-0761
December 20, 2010
- 2-Week Limit on Prescription Period Lifted for ARB/CCB Combination Drugs
December 20, 2010
- Astellas Enters into Strategic Equity Deal with Cytori
December 20, 2010
- Favorable Results for KW-0761 Also in US PI/PII Trial
December 20, 2010
- JMA Calls on Korosho to Reconsider Permission of Long-Term Prescriptions
December 20, 2010
- Kyowa Kirin Terminates License Agreement with LivTech for LIV-1205
December 20, 2010
- Favorable Long-Term PIII Results Published for Collategene: AnGes MG
December 20, 2010
- Revolade Benefits Patients with Intractable ITP: Prof. Ikeda
December 20, 2010
- Daiichi Sankyo Subsidiary Luitpold Acquires ROXRO PHARMA
December 20, 2010
- Daiichi Sankyo Completes Enrollment for Edoxaban PIII Trial
December 20, 2010
- Norspan Useful in Getting Doctors Conversant with Opioids: Prof. Ogawa
December 20, 2010
- Sanofi-aventis Extends Tender Offer for Genzyme Shares
December 20, 2010
- Novel Anticoagulants Gaining Popularity: Dr Yamashita
December 20, 2010
- Fixed-Dose Combination Eye Drops Improve Compliance: Dr Araie
December 20, 2010
- Mediscience to Acquire CRO Business from Tokyo Clinical CRO
December 20, 2010
- Industry Support Essential for iPS Cell Drug Discovery: Prof. Yamanaka
December 20, 2010
- NCGM Compiles Manual for Selection of Antidiabetic Drugs for GPs
December 20, 2010
- MTPC Takes Confidence-Building Measures
December 20, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…